Compare Novo Nordisk A/S (NVO) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Xylem, Inc. — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Xylem, Inc. trades at $117.66 (market cap $28.67B). The key difference: Novo Nordisk A/S is far larger — about 7.7× Xylem, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | XYL | |
|---|---|---|
Market Cap | $220.53B | $28.67B |
Sector | Health | Industrials |
52-Week High | $71.70 | $152.95 |
52-Week Low | $35.29 | $106.34 |
Enterprise Value | $239.49B | $29.92B |
Dividend Yield | 3.63% | 1.43% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
